Connect with us

Product Showcase

National Sickle Cell Anemia Eradication Mission 2047

Hon’ble Prime Minister Narendra Modi announced launch of National Sickle Cell Anemia Eradication Mission 2047 in MP.

Sickle Cell Disease is a disease that impacts tribal sections of societies significantly. The government is committed to eliminate the disease before India celebrates its Amrit Kaal in 2047.

This was stated by the Hon’ble Prime Minister of India, Shri Narendra Modi as he launched the National Sickle Cell Anemia Elimination Mission (NSCEM) in Shahdol, Madhya Pradesh.

Transasia introduces Made in India Erba sickle cell rapid test kits – A step toward combatting sickle cell anemia in line with the NSCEM program
Sickle cell disease (SCD) is a genetic blood disorder, where red blood cells contort into a sickle shape. Transasia Erba launched its latest innovation – the Made in India Erba sickle cell rapid test kits. With a focus on precision and accessibility, these kits mark a significant stride in aligning with Prime Minister Modi’s National Sickle Cell Anemia Elimination Mission (NSCEM) program.

Developed and manufactured at Transasia’s state-of-the-art facility in Andhra Pradesh MedTech Zone, Visakhapatnam, these kits epitomize the essence of Atmanirbhar Bharat, fostering self-reliance in crucial healthcare diagnostics. With a staggering production capacity of ten lakh kits per day, Transasia aims to address the urgent need for comprehensive sickle cell testing across the nation. This kit is suitable for screening individuals of any age group including adults as well infants.

Based on competitive lateral flow (immuno-chromatographic) format, these kits ensure accurate and swift detection, crucial for timely intervention and treatment. The kit aids in the detection of A and S type of hemoglobin (Hb) for clear differentiation between sickle cell disease and sickle cell trait. Some of the additional features include:

  • Available in two formats – A,S and A,S, C.
  • Only 10 uL of sample required.
  • No interference of fetal hemoglobin (HbF).
  • Results in 8–10 minutes.
  • No instrument required; can be used as point-of-care testing (POCT) in remote areas.
  • 100 percent sensitivity and specificity.
  • Approved by ICMR.

Furthermore, the versatility of these kits extends beyond conventional laboratory settings, making them ideal for surveillance and POCT in remote areas. This accessibility is paramount in reaching vulnerable populations, particularly in tribal communities, where sickle cell disease disproportionately affects individuals.

Transasia’s commitment to community health goes beyond innovation; it is about fostering awareness, education, and proactive screening initiatives. By collaborating with the government and private healthcare institutions, Transasia aims to deploy these kits strategically, ensuring they reach every corner of the nation, especially the states that are covered under the NSCEM program, viz., Gujarat, Maharashtra, Rajasthan, Madhya Pradesh, Jharkhand, Chhattisgarh, West Bengal, Odisha, Tamil Nadu, Telangana, Andhra Pradesh, Karnataka, Assam, Uttar Pradesh, Kerala, Bihar, and Uttarakhand.

Erba Transasia is also on the brink of launching the first-ever made in India qPCR sickle cell anemia test kit! The approval from the Indian Council of Medical Research (ICMR) for this accessible and affordable product fills us with commitment and joy.

Through collaboration, education, and access to reliable diagnostics, we can turn the tide against this silent but formidable adversary, one test kit at a time.

Copyright © 2024 Medical Buyer

error: Content is protected !!